Panacea Biotec Limited has informed the Exchange about General Updates

Business Updates View source PDF Explain this filing

PANACEABIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+13.6%Reaction day

₹383.00

prior close

₹401.30

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.9%+15.5% vs market

Pharmaceuticals peers, median of 154sector-1.9%+15.5% vs sector

On the reaction day the stock moved 15.5 pts more than Nifty Microcap 250 and 15.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.7

10m

+3.0

15m

+3.7

30m

+3.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+13.6-1.9+15.5-1.9+15.5

Next day

+4.9-3.6+8.5-2.8+7.8

+5.2-4.4+9.7-3.7+8.9

+3.5-4.1+7.6-4.0+7.5

+2.6-4.1+6.7-3.5+6.1

+4.6-4.5+9.2-4.5+9.1

+0.5-8.3+8.8-7.0+7.5

15d

-3.9-7.5+3.7-8.4+4.5

-3.4-2.1-1.3-5.6+2.2

-12.9-12.3-0.6-11.5-1.4

-13.1-7.4-5.6-9.2-3.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Panacea Biotec, along with ICMR, has completed enrollment of 10,335 study participants for the Phase III clinical trial of DengiAll®, its tetravalent dengue candidate vaccine. This follows the trial initiation announced in August 2024. Each participant will now be monitored for two years to assess the vaccine's efficacy and immunogenicity. DengiAll® is positioned as India's first indigenous single-shot dengue vaccine and is expected to reach the market by 2027.

Likely market impact

This is a positive development but commercial revenue is still 1-2 years away given the two-year monitoring period and expected 2027 launch. Shareholders should view this as a meaningful clinical milestone that de-risks the development pipeline, though no immediate financial impact is expected.